ClinicalTrials.gg

Program

olpasiran

Also written as “Olpasiran” and “AMG 890”.

Its studies are mostly in Cardiovascular Diseases · Atherosclerosis · Renal Insufficiency, led by Amgen.

Furthest: phase 3, since Oct 12, 20229 company-led studies, 3 open or runningNext primary completion: Mar 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen93 open or runningphase 3since Oct 12, 2022Jun 19, 2018Mar 31, 2028phase 3 · NCT05581303

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 19, 2018First study: phase 1 study in Cardiovascular DiseasesFirst studyNCT03626662 · 79 enrolled · United States, Australia
  2. Feb 13, 2020Phase 2 study in Cardiovascular DiseasesNCT04270760 · 281 enrolled · United States, Australia, Canada and more
  3. Jul 26, 2021Phase 1 study in Elevated Serum Lipoprotein(a)NCT04987320 · 24 enrolled · Hong Kong
  4. Jul 28, 2022Phase 1 study in Hepatic ImpairmentNCT05481411 · 25 enrolled · United States
  5. Aug 3, 2022Phase 1 study in Renal InsufficiencyNCT05489614 · 33 enrolled · United States
  6. Oct 12, 2022Phase 3 study in AtherosclerosisNCT05581303 · 7,297 enrolled · United States, Australia, Austria and more
  7. Apr 29, 2024Phase 1 study in Basic ScienceNCT06411860 · 32 enrolled · United Kingdom
  8. Aug 18, 2025Phase 3 study in Cardiovascular DiseasesNCT07136012 · 11,000 planned · United States, Australia, Canada and more
  9. Dec 17, 2025Phase 3 study in Cardiovascular DiseasesNCT07293260 · 406 planned · United States, Australia, Canada and more

Ahead

  1. Mar 31, 2028Primary completion: phase 3 study in AtherosclerosisNCT05581303
  2. Jun 15, 2028Primary completion: phase 3 study in Cardiovascular DiseasesNCT07293260
  3. Oct 20, 2031Primary completion: phase 3 study in Cardiovascular DiseasesNCT07136012

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07293260Cardiovascular Diseases · United States, Australia, Canada and more3RecruitingJun 15, 2028406
NCT07136012Cardiovascular Diseases · United States, Australia, Canada and more3RecruitingOct 20, 203111,000
NCT06411860Basic Science · United Kingdom1CompletedNov 29, 202432
NCT05581303Atherosclerosis · United States, Australia, Austria and more3Active, not recruitingMar 31, 20287,297
NCT05489614Renal Insufficiency · United States1CompletedOct 24, 202333
NCT05481411Hepatic Impairment · United States1CompletedApr 5, 202325
NCT04987320Elevated Serum Lipoprotein(a) · Hong Kong1CompletedNov 12, 202124
NCT04270760Cardiovascular Diseases · United States, Australia, Canada and more2CompletedDec 27, 2021281
NCT03626662Cardiovascular Diseases · United States, Australia1CompletedApr 18, 202379

How it is read

Names in the registry

  • “Olpasiran”, 8 entries
  • “AMG 890”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.